Advances in Targeting HER3 as an Anticancer Therapy

Author:

Jiang Ning12,Saba Nabil F.2,Chen Zhuo Georgia2

Affiliation:

1. State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangdong, Guangzhou 510060, China

2. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365-C Clifton Road, NE, Atlanta, GA 30322, USA

Abstract

HER3 (ErbB3) is a unique member of the human epidermal growth factor receptor (EGFR) family (ErbB family). It functions only through dimerization with other members of the ErbB family and modulates activity and sensitivity to targeted cancer therapies. This paper briefly describes the mechanism of HER3 in signal transduction and its potential role in acquired resistance to EGFR- and HER2-targeted therapies. We also consider recent developments in HER3-targeting therapeutics and their combination with inhibitors of other ErbB members in clinical applications.

Publisher

Hindawi Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,Oncology

Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Long road towards effective HER3 targeting in breast cancer;Cancer Treatment Reviews;2024-09

2. Combination Therapy as a Promising Way to Fight Oral Cancer;Pharmaceutics;2023-06-04

3. Comprehensive Assessment of OCR Tools for Gene Name Recognition in Biological Pathway Figures;2022 IEEE International Conference on Bioinformatics and Biomedicine (BIBM);2022-12-06

4. Beyond HER2: Targeting the ErbB receptor family in breast cancer;Cancer Treatment Reviews;2022-09

5. The diverse functions of FAT1 in cancer progression: good, bad, or ugly?;Journal of Experimental & Clinical Cancer Research;2022-08-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3